Alejandro Yovine
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.
Journal: Lancet (London, England)
Published: February 09, 2026
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.
Journal: The Lancet. Oncology
Published: May 08, 2024
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 13, 2022
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 12, 2022
Curative-Intent Treatment with Durvalumab in Early-Stage Cancers.
Journal: Advances in therapy
Published: January 22, 2021
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Journal: The Lancet. Oncology
Published: October 09, 2015
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 10, 2013
Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
Journal: Molecular cancer therapeutics
Published: February 28, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026